{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T14:54:58Z","timestamp":1772463298137,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T00:00:00Z","timestamp":1530662400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shanghai Municipal Science and Technology Commission of biological medicine","award":["No.12411950500"],"award-info":[{"award-number":["No.12411950500"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81772107"],"award-info":[{"award-number":["No. 81772107"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 81571931"],"award-info":[{"award-number":["No. 81571931"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Shen Kang Hospital Development Center Clinical Science and technology innovation project","award":["SHDC12017116"],"award-info":[{"award-number":["SHDC12017116"]}]},{"name":"Important and weak discipline construction plan for health and family planning system of Shanghai","award":["2016ZB0206"],"award-info":[{"award-number":["2016ZB0206"]}]},{"name":"Program for Outstanding Medical Academic Leader of Shanghai","award":["2018ChenErzhen"],"award-info":[{"award-number":["2018ChenErzhen"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40360-018-0226-1","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T08:48:01Z","timestamp":1530694081000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Polymyxin B-induced skin hyperpigmentation: a rare case report and literature review"],"prefix":"10.1186","volume":"19","author":[{"given":"Guanhao","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zaiqian","family":"Che","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enqiang","family":"Mao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erzhen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,7,4]]},"reference":[{"issue":"4","key":"226_CR1","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2165\/00128071-200102040-00006","volume":"2","author":"O Dereure","year":"2001","unstructured":"Dereure O. Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment. Am J Clin Dermatol. 2001;2(4):253.","journal-title":"Am J Clin Dermatol"},{"issue":"7","key":"226_CR2","first-page":"644","volume":"11","author":"W Krause","year":"2013","unstructured":"Krause W. Drug-induced hperpigemntation: a systematic review. J Dtsch Dermatol Ges. 2013;11(7):644\u201351.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"2","key":"226_CR3","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1473-3099(14)70850-3","volume":"15","author":"RL Nation","year":"2015","unstructured":"Nation RL, Li J, Cars O, Couet W, Dudley MN, Kaye KS, Mouton JW, Paterson DL, Tam VH, Theuretzbacher U. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis. 2015;15(2):225.","journal-title":"Lancet Infect Dis"},{"issue":"6","key":"226_CR4","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.ijantimicag.2016.09.010","volume":"48","author":"TB Tran","year":"2016","unstructured":"Tran TB, Velkov T, Nation RL, Forrest A, Tsuji BT, Bergen PJ, Li J. Pharmacokinetics\/pharmacodynamics of colistin and polymyxin B: are we there yet? Int J Antimicrob Agents. 2016;48(6):592\u20137.","journal-title":"Int J Antimicrob Agents"},{"key":"226_CR5","doi-asserted-by":"crossref","unstructured":"Velkov T, Dai C, Ciccotosto GD, Cappai R, Hoyer D, Li J. Polymyxins for CNS infections: pharmacology and neurotoxicity. Pharmacol Ther. 2017;","DOI":"10.1016\/j.pharmthera.2017.07.012"},{"issue":"11","key":"226_CR6","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1517\/14740338.2015.1088520","volume":"14","author":"T Kelesidis","year":"2015","unstructured":"Kelesidis T, Falagas ME. The safety of polymyxin antibiotics. Expert Opin Drug Saf. 2015;14(11):1687\u2013701.","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"226_CR7","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1086\/518706","volume":"45","author":"RC Knueppel","year":"2007","unstructured":"Knueppel RC, Rahimian J. Diffuse cutaneous hyperpigmentation due to tigecycline or polymyxin B. Clin Infect Dis. 2007;45(1):136.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"226_CR8","first-page":"FD01","volume":"11","author":"S Lahiry","year":"2017","unstructured":"Lahiry S, Choudhury S, Mukherjee A, Bhunya PK, Bala M. Polymyxin B-induced diffuse cutaneous hyperpigmentation. J Clin Diagn Res. 2017;11(2):FD01\u20132.","journal-title":"J Clin Diagn Res"},{"issue":"2","key":"226_CR9","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s12098-015-1798-z","volume":"83","author":"S Gothwal","year":"2016","unstructured":"Gothwal S, Meena K, Sharma SD, Polymyxin B. Induced generalized hyperpigmentation in neonates. Indian J Pediatr. 2016;83(2):179\u201380.","journal-title":"Indian J Pediatr"},{"key":"226_CR10","doi-asserted-by":"crossref","unstructured":"Shih LK, Gaik CL. Polymyxin B induced generalized skin hyperpigmentation in infants. J Pediatr Scis. 2014;6:e215.","DOI":"10.17334\/jps.10375"},{"issue":"3","key":"226_CR11","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1111\/pcmr.12468","volume":"29","author":"KP Mattos","year":"2016","unstructured":"Mattos KP, Lloret GR, Cintra ML, Gouvea IR, Betoni TR, Mazzola PG, Moriel P. Acquired skin hyperpigmentation following intravenous polymyxin B treatment: a cohort study. Pigment Cell Melanoma Res. 2016;29(3):388\u201390.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"5","key":"226_CR12","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/jcpt.12543","volume":"42","author":"KPH Mattos","year":"2017","unstructured":"Mattos KPH, Cintra ML, Gouvea IR, Ferreira LA, Velho P, Moriel P. Skin hyperpigmentation following intravenous polymyxin B treatment associated with melanocyte activation and inflammatory process. J Clin Pharm Ther. 2017;42(5):573\u20138.","journal-title":"J Clin Pharm Ther"},{"issue":"10","key":"226_CR13","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1002\/j.1552-4604.1992.tb04635.x","volume":"32","author":"CA Naranjo","year":"1992","unstructured":"Naranjo CA, FRCPC DNHSM, Lanct\u00f4t MKL. Advances in the diagnosis of adverse drug reactions. J Clin Pharmacol. 1992;32(10):897\u2013904.","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"226_CR14","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"226_CR15","doi-asserted-by":"publisher","first-page":"ofw033","DOI":"10.1093\/ofid\/ofw033","volume":"3","author":"SJ Vandecasteele","year":"2016","unstructured":"Vandecasteele SJ, De Ceulaer J, Wittouck E. Tigecycline induced hyperpigmentation of the skin. Open Forum Infect Dis. 2016;3(1):ofw033.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"226_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/0006-2952(93)90346-X","volume":"46","author":"GA Fechner","year":"1993","unstructured":"Fechner GA, Jacobs JJ, Parsons PG. Inhibition of melanogenesis in human melanoma cells by novel analogues of the partial histamine (H2) agonist nordimaprit. Biochem Pharmacol. 1993;46(1):47.","journal-title":"Biochem Pharmacol"},{"issue":"1-2","key":"226_CR17","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF01969025","volume":"30","author":"VG Voitenko","year":"1990","unstructured":"Voitenko VG, Bayramashvili DI, Zebrev AI, Zinchenko AA. Relationship between structure and histamine releasing action of polymyxin B and its analogues. Agents Actions. 1990;30(1-2):153.","journal-title":"Agents Actions"},{"issue":"4 Suppl","key":"226_CR18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/S0091-6749(03)01881-5","volume":"112","author":"G Marone","year":"2003","unstructured":"Marone G, Granata F, Spadaro G, Genovese A, Triggiani M. The histamine-cytokine network in allergic inflammation. J Allergy Clin Immunol. 2003;112(4 Suppl):83\u20138.","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"226_CR19","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1046\/j.1523-1747.2000.00874.x","volume":"114","author":"M Yoshida","year":"2000","unstructured":"Yoshida M, Takahashi Y, Inoue S. Histamine induces Melanogenesis and morphologic changes by protein kinase a activation via H2 receptors in human normal melanocytes. J Investig Dermatol. 2000;114(2):334\u201342.","journal-title":"J Investig Dermatol"},{"issue":"6","key":"226_CR20","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1097\/00000372-199012000-00011","volume":"12","author":"L Miori","year":"1990","unstructured":"Miori L, Vignini M, Rabbiosi G. Flagellate dermatitis after bleomycin. A histological and immunohistochemical study. Am J Dermatopathol. 1990;12(6):598\u2013602.","journal-title":"Am J Dermatopathol"},{"issue":"3","key":"226_CR21","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.jdermsci.2012.03.002","volume":"66","author":"H Choi","year":"2012","unstructured":"Choi H, Kim K, Han J, Choi H, Jin SH, Lee EK, Shin DW, Lee TR, Lee AY, Noh M. Kojic acid-induced IL-6 production in human keratinocytes plays a role in its anti-melanogenic activity in skin. J Dermatol Sci. 2012;66(3):207\u201315.","journal-title":"J Dermatol Sci"},{"issue":"10","key":"226_CR22","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1177\/1060028015595643","volume":"49","author":"AP Zavascki","year":"2015","unstructured":"Zavascki AP, Manfro RC, Maciel RA, Falci DR. Head and neck hyperpigmentation probably associated with Polymyxin B therapy. Ann Pharmacother. 2015;49(10):1171\u20132.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"226_CR23","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/j.ijantimicag.2016.08.010","volume":"48","author":"AP Zavascki","year":"2016","unstructured":"Zavascki AP, Schuster LF, Duquia RP. Histopathological findings of pigmented lesion and recovery of natural skin colour in a patient with polymyxin B-associated diffuse hyperpigmentation. Int J Antimicrob Agents. 2016;48(5):579\u201380.","journal-title":"Int J Antimicrob Agents"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0226-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40360-018-0226-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-018-0226-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,22]],"date-time":"2019-09-22T04:37:01Z","timestamp":1569127021000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-018-0226-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,4]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["226"],"URL":"https:\/\/doi.org\/10.1186\/s40360-018-0226-1","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7,4]]},"assertion":[{"value":"27 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by Ruijin Hospital Institutional Review Board and has been performed in accordance with the ethical standards laid down in \u201cDeclaration of Helsinki 1964\u201d and its later amendments or comparable ethical standards. One patient was enrolled in the study and informed consent forms were signed by this patient.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient to the publication of this case report. A copy of the written informed consent is available for the review by the editor of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"41"}}